目的: 在痕量水平基因毒性杂质甲磺酸酯（甲磺酸甲酯、甲磺酸乙酯、甲磺酸丙酯和甲磺酸异丙酯）的稳定性及水解动力学研究。方法: 以乙腈-水（80∶20, v/v）为溶剂配制甲磺酸酯混合溶液, 分别置于298、313 及323 K 温度下, 定时取样并加入碘化钠衍生化溶液, 分别得到相应的碘代烷烃（碘甲烷、碘乙烷、碘丙烷和碘代异丙烷）, 采用顶空法进行气相色谱-质谱测定。结果: 甲磺酸乙酯和甲磺酸丙酯在上述不同温度下均具有较好的稳定性, 而甲磺酸甲酯和甲磺酸异丙酯仅在室温条件下具有较好的稳定性。随着温度升高至313 K 和 323 K, 甲磺酸甲酯和甲磺酸异丙酯均发生了酯基水解反应, 并测得相应的水解反应动力学参数。结论: 通过本研究揭示了不同甲磺酸酯的稳定性属性, 并由此提示了在检测方法学开发中应特别留意甲磺酸酯溶液放置温度条件的控制, 以保证检测结果的准确性。
Objective: To study the stability and hydrolysis kinetics of genotoxic impurities methanesulfonates at trace levels, including methyl methanesulfonate（MMS）, ethyl methanesulfonate（EMS）, propyl methanesulfonate （PMS）and isopropyl methanesulfonate（IMS）. Methods: Solutions of methansulfonates were prepared in acetonitrile/water（80∶20, v/v）and placed under 298 K, 313 K and 323 K, respectively. The methanesulfonates solutions were transformed into corresponding alkyl iodides for headspace GC/MS detection by utilizing the sodium iodide solution as the derivative reagent. The concentrations of the methansulfonates were monitored periodically by their corresponding derivative products of alkyl iodides. Results: EMS and PMS were stable under the above mentioned temperatures, while MMS and IMS were found to be stable only under 298 K. As the temperature raised to 313 K and 323 K, both MMS and IMS degraded due to the hydrolysis reaction on their corresponding ester groups. Both the hydrolysis kinetic parameters were obtained. Conclusion: Different kinds of methanesulfonates possess characteristic stability properties, whereas, indicating that serious attentions should be paid on the strict requirements of the temperature control for preparing the sample solutions during assay determinations.
[1] MÜLLER L, MAUTHE RJ, RILEY CM, et al. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity[J]. Regul Toxicol Pharm, 2006, 44(3): 198
[2] European Medicines Agency. European Medicines Agency agrees on action plan following the recall of Viracept and recommends suspension of the Marketing Authorisation[EB/OL]. (2007-06-21)[2020-11-24]. https://www.ema.europa.eu/en/documents/press-release/european-medicines-agency-agrees-action-planfollowing-recall-viracept-recommends-suspension_en.pdf
[3] The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Guideline M7(R1): Assessment and control of DNA reactive (mutagenic)impurities in pharmaceuticals to limit potential carcinogenic risk[EB/OL]. 2017[2020-11-24]. https://www.ich.org/page/multidisciplinary-guidelines
[4] European Medicines Agency. EMA reviewing medicines containing Valsartan from Zhejiang Huahai following detection of an impurity[EB/OL]. (2018-07-05)[2020-11-24]. https://www.ema.europa.eu/en/documents/press-release/ema-reviewing-medicines-containingvalsartan-zhejiang-huahai-following-detection-impurity_en.pdf
[5] U. S. Food and Drug Administration. Search list of recalled Angiotensin II Receptor Blockers(ARBs)including Valsartan, Losartan and Irbesartan[EB/OL]. (2019-09-23)[2020-11-24]. https://www.fda.gov/drugs/drug-safety-and-availability/searchlist-recalled-angiotensin-ii-receptor-blockers-arbs-includingvalsartan-losartan-and
[6] U. S. Food and Drug Administration. FDA requests removal of all Ranitidine products(Zantac)from the market[EB/OL]. (2020-04-01)[2020-04-05]. https://www.fda.gov/news-events/pressannouncements/fda-requests-removal-all-ranitidine-productszantac-market
[7] KAKADIYA PR, REDDY BP, SINGH V, et al. Low level determinations of methyl methanesulfonate and ethyl methanesulfonate impurities in Lopinavir and Ritonavir active pharmaceutical ingredients by LC/MS/MS using electrospray ionization[J]. J Pharm Biomed Anal, 2011, 55(2): 379
[8] GUO T, SHI YY, ZHENG L, et al. Rapid and simultaneous determination of sulfonate ester genotoxic impurities in drug substance by liquid chromatography coupled to tandem mass spectrometry: Comparison of different ionization mode[s J]. J Chromatogr A, 2014, 1355: 73
[9] 陈成, 尹璐, 王媛, 等. LC-MS/MS 法测定2-脱氧-D-核糖中的甲磺酸甲酯和甲磺酸乙酯的含量[J]. 沈阳药科大学学报, 2015, 32(9): 695
CHEN C, YIN L, WANG Y, et al. A convenient LC-MS/MS method for determination of methyl methanesulfonate and ethyl methanesulfonate in 2-deoxy-D-ribose[J]. J Shenyang Pharm Univ, 2015, 32(9): 695
[10] ZHOU J, XU J, ZHENG XY, et al. Determination of methyl methanesulfonate and ethyl methanesulfonate in methanesulfonic acid by derivatization followed by high‐performance liquid chromatography with ultraviolet detection[J]. J Sep Sci, 2017, 40(17): 3414
[11] LI WY. Trace analysis of residual methyl methanesulfonate, ethyl methanesulfonate and isopropyl methanesulfonate in pharmaceuticals by capillary gas chromatography with flame ionization detection[J]. J Chromatogr A, 2004, 1046: 297
[12] 范达, 涂家生. 顶空气相色谱法测定注射用甲磺酸吉米沙星中基因毒性杂质[J]. 药学进展, 2014, 38(3): 220
FAN D, TU JS. Determination of genotoxic impurities in gemifloxacin mesylate for injection by head-space GC[J]. Prog Pharm Sci, 2014, 35(3): 220
[13] AN JG, SUN MJ, BAI L, et al. A practical derivatization LC/MS approach for determination of trace level alkyl sulfonates and dialkyl sulfates genotoxic impurities in drug substances[J]. J Pharm Biomed Anal, 2008, 48(3): 1006
[14] LI MX, GU CC, LUO L, e t a l. Determination of trace methanesulfonates in drug matrix using derivatization and headspace single drop microextraction followed by high-performance liquid chromatography with ultraviolet detection[J]. J Chromatogr A, 2019, 1591: 131
[15] ALZAGA R, RYAN RW, TAYLOR-WORTH K, et al. A generic approach for the determination of residues of alkylating agents in active pharmaceutical ingredients by in situ derivatizationheadspace-gas chromatography-mass spectrometry[J]. J Pharm Biomed Anal, 2007, 45(3): 472
[16] RAMAKRISHNA K, RAMAN NVVSS, RAO KMVN, et al. Development and validation of GC-MS method for the determination of methyl methanesulfonate and ethyl methanesulfonate in imatinib mesylate[J]. J Pharm Biomed Anal, 2008, 46(4): 780
[17] WOLLEIN U, SCHRAMEK N. Simultaneous determination of alkyl mesilates and alkyl besilates in finished drug products by direct injection GC/MS[J]. Eur J Pharm Sci, 2012, 45(1-2): 201
[18] SUN MJ, LIU DQ, KORD AS. A systematic method development strategy for determination of pharmaceutical genotoxic impurities[J]. Org Process Res Dev, 2010, 14(4): 977
[19] LIU DQ, SUN MJ, KORD AS. Recent advances in trace analysis of pharmaceutical genotoxic impurities[J]. J Pharm Biomed Anal, 2010, 51(5): 999
[20] REDDY AV, JAAFAR J, UMAR K, et al. Identification, control strategies, and analytical approaches for the determination of potential genotoxic impurities in pharmaceuticals: a comprehensive review[J]. J Sep Sci, 2015, 38(5): 764
